These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9187131)

  • 1. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6.
    Billadeau D; Liu P; Jelinek D; Shah N; LeBien TW; Van Ness B
    Cancer Res; 1997 Jun; 57(11):2268-75. PubMed ID: 9187131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6.
    Billadeau D; Jelinek DF; Shah N; LeBien TW; Van Ness B
    Cancer Res; 1995 Aug; 55(16):3640-6. PubMed ID: 7627974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response.
    Rowley M; Van Ness B
    Oncogene; 2002 Dec; 21(57):8769-75. PubMed ID: 12483530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.
    Rowley M; Liu P; Van Ness B
    Blood; 2000 Nov; 96(9):3175-80. PubMed ID: 11050000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growth.
    Crowder C; Kopantzev E; Williams K; Lengel C; Miki T; Rudikoff S
    Oncogene; 2003 Feb; 22(5):649-59. PubMed ID: 12569357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro.
    Cheung WC; Van Ness B
    Leukemia; 2001 Feb; 15(2):264-71. PubMed ID: 11236942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Requirement of soluble factors produced by bone marrow stromal cells on the growth of novel established human myeloma cell line.
    Aikawa S; Hatta Y; Tanaka M; Kaneita Y; Yasukawa K; Sawada U; Horie T; Tsuboi I; Aizawa S
    Int J Oncol; 2003 Mar; 22(3):631-7. PubMed ID: 12579318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice.
    Zhang YA; Nemunaitis J; Scanlon KJ; Tong AW
    Gene Ther; 2000 Dec; 7(23):2041-50. PubMed ID: 11175317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
    Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting inhibition of K-ras enhances Ad.mda-7-induced growth suppression and apoptosis in mutant K-ras colorectal cancer cells.
    Lebedeva IV; Su ZZ; Emdad L; Kolomeyer A; Sarkar D; Kitada S; Waxman S; Reed JC; Fisher PB
    Oncogene; 2007 Feb; 26(5):733-44. PubMed ID: 16924242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenes in multiple myeloma: point mutation of N-ras.
    Paquette RL; Berenson J; Lichtenstein A; McCormick F; Koeffler HP
    Oncogene; 1990 Nov; 5(11):1659-63. PubMed ID: 2267133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells.
    Wang YD; De Vos J; Jourdan M; Couderc G; Lu ZY; Rossi JF; Klein B
    Oncogene; 2002 Apr; 21(16):2584-92. PubMed ID: 11971193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells.
    Taetle R; Dos Santos B; Akamatsu K; Koishihara Y; Ohsugi Y
    Clin Cancer Res; 1996 Feb; 2(2):253-9. PubMed ID: 9816167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autocrine interleukin-1beta production in leukemia: evidence for the involvement of mutated RAS.
    Beaupre DM; Talpaz M; Marini FC; Cristiano RJ; Roth JA; Estrov Z; Albitar M; Freedman MH; Kurzrock R
    Cancer Res; 1999 Jun; 59(12):2971-80. PubMed ID: 10383163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
    Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
    Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors.
    Jourdan M; Mahtouk K; Veyrune JL; Couderc G; Fiol G; Redal N; Duperray C; De Vos J; Klein B
    Eur Cytokine Netw; 2005; 16(1):57-64. PubMed ID: 15809207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration.
    Giehl K; Skripczynski B; Mansard A; Menke A; Gierschik P
    Oncogene; 2000 Jun; 19(25):2930-42. PubMed ID: 10871844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relevance of Ras gene mutations in the context of the molecular heterogeneity of multiple myeloma.
    Intini D; Agnelli L; Ciceri G; Ronchetti D; Fabris S; Nobili L; Lambertenghi-Deliliers G; Lombardi L; Neri A
    Hematol Oncol; 2007 Mar; 25(1):6-10. PubMed ID: 17036375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
    Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
    Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of sphingosine kinase mediates suppressive effect of interleukin-6 on human multiple myeloma cell apoptosis.
    Li QF; Wu CT; Duan HF; Sun HY; Wang H; Lu ZZ; Zhang QW; Liu HJ; Wang LS
    Br J Haematol; 2007 Sep; 138(5):632-9. PubMed ID: 17686057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.